A peptide COA is not a marketing attachment. It is a batch-specific quality document that should help a research buyer determine whether the material received matches the material ordered, how it was evaluated, and where uncertainty remains. Knowing how to read peptide COA documentation is therefore part of basic incoming-material control, especially when a project depends on repeatable handling and batch-to-batch consistency.
A Certificate of Analysis can support a purchasing decision, but it does not replace method review, fit-for-purpose qualification, or independent verification when a study requires it. Read it as evidence tied to a defined lot, not as a blanket statement about every vial, every future batch, or every possible research application.
How to Read Peptide COA Documentation
Start by confirming that the document belongs to the exact material in hand. The product name should match the purchase record, including the peptide form where relevant. A label such as “BPC-157” alone may be insufficient if the supplier offers multiple salt forms, package sizes, or presentations.
The lot or batch number is the central control point. It should match the lot number on the vial or outer packaging. If the COA identifies a different batch, a generic sample, or no lot at all, it cannot substantiate the specific material received. A valid document should also identify the testing or issue date and, ideally, the manufacture date or retest date.
Next, look for the material description. This often includes the peptide name, sequence, molecular formula, molecular weight, salt form, and physical appearance. These fields establish what the supplier claims to have tested. They are useful, but they carry different evidentiary weight. A stated sequence is a product specification; mass spectrometry data is stronger evidence that the observed mass is consistent with the intended peptide.
Identity: Confirm the Material Before Reading Purity
Identity testing answers a basic question: is the major component consistent with the peptide named on the label? For research-grade peptides, LC-MS or another appropriate mass spectrometry method is commonly used for this purpose.
Review the expected molecular weight against the observed result. Small differences may be explainable by the reported ion form, charge state, salt association, hydration, or how the instrument reports mass. The relevant question is not whether two numbers look identical at a glance. It is whether the reported result is scientifically consistent with the expected analyte and the method used.
A credible COA should state the identity test and report a result, such as a measured mass or a passing identification finding. A simple “Pass” can be acceptable only when the method, acceptance criteria, and supporting information are available elsewhere in the document or upon request. A mass spectrum is more informative than a bare statement because it allows a technically informed buyer to assess the reported peak pattern and molecular mass assignment.
Identity confirmation is not the same as purity confirmation. A sample can contain the intended peptide and still include meaningful levels of truncations, deletion sequences, oxidation products, residual synthesis-related compounds, or other impurities. That distinction is where many COA reviews become too superficial.
Sequence, mass, and salt form
Peptide names can conceal meaningful differences in presentation. Acetate, trifluoroacetate, hydrochloride, or other counterions may affect reported mass, net peptide content, hygroscopic behavior, and how a result is described on the COA. The counterion should not be treated as an afterthought when comparing lots or calculating actual peptide content.
For the same reason, do not assume that vial fill weight equals active peptide content. If a vial is labeled by total mass, that mass may include peptide plus water, residual solvent, counterions, or other non-peptide components. The COA should make clear whether its reported quantity refers to gross material, peptide content, or another basis.
Purity: Understand What the Percentage Actually Means
Most peptide COAs report purity using HPLC, often reverse-phase HPLC. The reported percentage generally represents the relative area of the principal chromatographic peak under the stated method. A result such as 99% purity is meaningful only in the context of that method, detector, integration approach, and sample preparation.
Read the analytical method before relying on the percentage. A useful COA identifies the technique, such as RP-HPLC, the detection wavelength, and the result. More complete documentation may include column information, mobile phases, gradient conditions, retention time, chromatogram, and acceptance criteria. Not every purchasing decision requires the full method package, but the more consequential the research, the more valuable that context becomes.
A chromatogram should show a dominant main peak with limited secondary peaks. It should also be legible enough to evaluate. A cropped image with no axes, no retention-time scale, or no sample identifier offers little practical assurance. Review whether the sample or lot number on the chromatogram aligns with the COA and whether the reported purity plausibly matches the displayed integration.
Purity is method-dependent. HPLC may reveal chromatographically distinguishable impurities, but it does not independently establish every possible contaminant class. A high HPLC area percentage does not automatically demonstrate low endotoxin, low bioburden, solvent compliance, elemental impurity control, sterility, or accurate fill quantity. Those require separate testing and separate documentation.
Assay, Content, and Purity Are Not Interchangeable
This is one of the most consequential distinctions in peptide procurement. Purity describes the proportion of the main chromatographic component under a specific method. Assay or peptide content addresses how much actual peptide is present in the supplied material. Net content addresses the amount available in the container.
These measurements can move independently. A material may produce a clean chromatographic profile while carrying water or counterions that reduce net peptide content by weight. Conversely, a reported vial mass does not establish that the expected amount of target peptide is available for research use.
When project planning depends on accurate mass balance, ask what the reported value represents. Check whether the supplier provides peptide content by amino acid analysis, quantitative NMR, nitrogen analysis, or another validated approach. The appropriate method depends on the compound and research requirement. For early-stage screening, identity and chromatographic purity may be sufficient. For work where concentration control or lot comparability is critical, content data becomes more relevant.
Review the COA as a Controlled Record
A professional COA should read like a controlled quality record rather than a generic product sheet. At minimum, evaluate whether it includes the following elements:
- Product name and unambiguous material identification
- Lot or batch number matching the received material
- Test methods and reported results for identity and purity
- Specifications or acceptance criteria, not only favorable results
- Issue date, analyst or quality authorization, and document control details
- Storage guidance and, where applicable, retest or expiration information
A signature, approval field, or quality-control authorization matters because it indicates that the document has passed through a defined release process. Digital approval is common and can be appropriate. What matters is traceability and accountability, not whether the signature is handwritten.
Storage information deserves attention because peptide stability can be affected by temperature, moisture, light exposure, repeated handling, and reconstitution conditions. A COA does not establish that shipping and post-delivery storage were controlled, but it should give the buyer a basis for setting receiving and storage procedures. Document the condition of the package on receipt when the material will support sensitive research.
Questions a COA May Not Answer
A COA is valuable, but it has limits. It may not disclose the sampling plan, raw data, method validation status, instrument calibration status, laboratory accreditation, chain of custody, or testing performed by an independent laboratory. It may also omit tests that are highly relevant for a particular workflow.
For example, endotoxin testing may matter in certain biological research contexts, while residual solvent analysis may matter when synthesis-process carryover is a concern. Microbial limits, elemental impurities, water content, and counterion quantification may also be relevant depending on the material, study design, and institutional requirements. The right question is not whether every COA contains every test. The right question is whether the available evidence is proportionate to the risk and intended research use.
If a supplier provides only a generic purity statement, no lot-specific document, or results that cannot be tied to a stated method, treat the documentation as incomplete. Do not fill the gaps with assumptions. Request clarification, compare the document with the product label, and establish whether the supplier can provide batch-level analytical support.
A Practical Receiving Review for Research Buyers
Build the COA review into the receiving process rather than treating it as an after-purchase task. Verify the purchase order, product label, lot number, package condition, and COA together. Save the document in the same record system used for the material itself, so future results can be traced back to a specific batch.
For repeat purchases, compare new lots against prior lots. Look for changes in reported purity, retention time, mass result, salt form, storage conditions, or specification language. A changed value is not automatically a defect, but unexplained changes can affect continuity across a research program. Consistency is established through documented comparison, not through a single favorable number.
At FenaLife, COA access and batch-level quality information support a quality-first purchasing process for research-use materials. Those documents should be reviewed alongside your own laboratory controls, not used as a substitute for them.
The most useful COA is one that lets you ask better questions: Does this document match this lot? Does the method support the claim? Does the stated result address the risk that matters to this study? When those answers are clear, the material can enter a research workflow with a stronger, more defensible quality record.